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Tissue repair is an essential compo-
nent of wound healing and resolution
of inflammation that, when uncontrolled,
can lead to excessive scarring and organ
failure (Majno, 1991). Indeed, exagger-
ated and persistent extracellular matrix
(ECM) deposition in tissues is the hall-
mark of many pathologies linked to non-
resolving inflammation, such as asthma,
chronic obstructive pulmonary disease,
and atherosclerosis (Nathan and Ding,
2010; Serhan et al., 2010; Tabas and Glass,
2013). Systemic fibrosis, also called scle-
roderma (SSc) is a rare, often idiopathic,
autoimmune disease in which a chronic
inflammation leads to diffuse fibrosis in
several organs, mainly skin, lungs, kid-
neys, eyes, heart, liver (Shah and Wigley,
2014). Despite considerable advances, this
pathology, which affects several million
of individuals worldwide, is still without
a specific and effective therapy (Canady
et al., 2013)
The ancient dogma that fibrosis orig-
inates from hyperactivation or deregula-
tion of tissue resident fibroblasts by the
local milieu of cytokines and growth fac-
tors has been challenged by accruing evi-
dence signifying now that many cells can
contribute to the pathogenesis of fibro-
sis. These include bone marrow (BM)-
derived monocytes that can differentiate
into “fibrocytes,” i.e., collagen-producing
leukocytes (Bucala et al., 1994), that
can not only release ECM proteins, but
also secrete pro-inflammatory cytokines,
chemokines, and growth factors that
amplify the pro-fibrotic process in a
vicious circle (Metz, 2003). Hence, bone
marrow derived fibrocytes represent an
important cellular target in SSC and other
chronic diseases.
It is well documented that in fibrotic
diseases caveolin (Cav)-1 expression is
profoundly reduced in fibroblast and
monocytes. Cav-1 is a master regulator of
several kinases downstream of growth fac-
tor, chemokines, and cytokine receptors, as
well as many other cellular functions [e.g.,
ECM adhesion, lipid transport, and mem-
brane traffic (Boscher and Nabi, 2012)].
Lack of Cav-1 in SSc patients and nulli-
fiedmice results in collagen overexpression
and monocyte hypermigration. Therefore,
in recent years, Cav-1 has been object
of intense scrutiny as possible molecu-
lar pharmaceutical target to treat SSc and
other fibrotic diseases (Tourkina et al.,
2008).
In this Research Topic of Frontiers in
Pharmacology named The Cell Types of
Fibrosis, Lee et al. (2014) demonstrate
that treatment with a Cav-1 scaffolding
domain peptide (CSD) spanning amino
acids 82–101 of the full protein inhibits
dermal fibrosis and lipodystrophy in a
mouse model of bleomycin-induced fibro-
sis that closely mimic the histopathology
of skin observed in clinical situations
of SSc. Namely, the authors demonstrate
that CSD significantly reduced accumu-
lation in skin and dermis of SSc mice
of chemokine receptor (CCR) 5 posi-
tive monocytes and fibrocytes, which are
increased in fibrotic lesions of SSc mice
and SSc patients, and ameliorated the
clinical signs of skin fibrosis. Moreover,
CSD treatment reduced migration of SSc
monocytes toward CCR5 ligands and
diminished receptor expression in SSc
monocytes.
These results represent a step for-
ward toward the exploitation of Cav-1
directed therapeutics for the treatment of
SSc and open the road for further stud-
ies aimed at establishing the molecular
mechanisms by which CSD protects from
fibrosis. For instance, additional stud-
ies could investigate whether CSD acts
by re-establishing the correct turnover of
CCR5 upon engagement to its ligands.
Or, whether CSD modifies the phenotype
of BM-derived fibrocytes (e.g., reducing
their capability of secreting ECM compo-
nents and other pro-fibrotic mediators).
Furthermore, the study of Lee and col-
leagues provides proof of concept for test-
ing CSD for the treatment of fibrosis in
different pathologies characterized by a
deregulation of monocyte plasticity and
functions. For example, in atherosclerotic
plaque monocyte-macrophages can either
differentiate into lipid rich “foam cells”
and secrete factors that sustain atheroma
formation or can be stimulated to pro-
mote resolution (Moore and Tabas, 2011;
Randolph, 2014). Likewise, macrophages
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accumulate in obese fat tissues (Weisberg
et al., 2003) and have a distinct signature of
lipid mediators, cytokines, and adipokines
in obesity that can be skewed to limit the
inflammatory tone (Hellmann et al., 2011;
Titos et al., 2011). Finally, lung fibrosis is
a hallmark of chronic respiratory patholo-
gies such as asthma, chronic obstructive
pulmonary disease, and cystic fibrosis in
which airways are repeatedly exposed to
insults (Levy and Serhan, 2014). Whether
Cav-1 deficiency and increased infiltra-
tion of BM-derived fibrocytes also occur in
these and other illnesses, and whether CSD
treatment proves therapeutically effective
is of paramount interest.
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